| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Center for Immunology, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455
Tumor membrane Ag immobilized on cell size microspheres (large multivalent immunogen (LMI)) was previously shown to augment tumor-specific CTL activity and reduce tumor growth, and a clinical trial examining this approach is in progress. In the current study, LMI treatment has been examined using adoptive transfer of TCR-transgenic CD8 T cells to visualize Ag-specific cells during the response. OT-I T cells specific for H-2Kb/OVA257–264 were transferred into mice that were then challenged with LMI made by immobilizing H-2Kb/OVA257–264 on microspheres (Kb/OVA257–264-LMI) alone, or along with i.p. challenge with OVA-expressing E.G7 tumor. Kb/OVA257–264-LMI caused significant reduction of tumor growth when administered to E.G7-bearing mice. When administered alone, the Kb/OVA257–264-LMI caused only weak clonal expansion of OT-I cells in the spleen and lymph nodes, although most of the OT-I cells up-regulated expression of CD44 and VLA-4. In contrast, Kb/OVA257–264-LMI administration to E.G7-bearing mice stimulated no detectable expansion of OT-I cells in the spleen and lymph nodes but caused a rapid increase in the number of OT-I cells in the peritoneal cavity, the site of the growing tumor. These results demonstrate the potential for using class I/tumor peptide complexes for immunotherapy. In addition, they suggest a model for the mechanism of CTL augmentation in which recognition of the LMI Ag results in altered trafficking of the tumor-specific CD8 T cells so that they reach the site of a growing tumor more rapidly and in greater numbers, where they may further expand and acquire effector function.
This article has been cited by other articles:
|
|
 |
|
  S. Caserta, P. Alessi, J. Guarnerio, V. Basso, and A. Mondino Synthetic CD4+ T Cell-Targeted Antigen-Presenting Cells Elicit Protective Antitumor Responses Cancer Res., April 15, 2008; 68(8): 3010 - 3018. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Schutz, M. Fleck, A. Mackensen, A. Zoso, D. Halbritter, J. P. Schneck, and M. Oelke Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells Blood, April 1, 2008; 111(7): 3546 - 3552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tao, B. H. Segal, C. Eppolito, Q. Li, C. G. Dennis, R. Youn, and P. A. Shrikant Aspergillus fumigatus extract differentially regulates antigen-specific CD4+ and CD8+ T cell responses to promote host immunity J. Leukoc. Biol., September 1, 2006; 80(3): 529 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Heeger, P. N. Lalli, F. Lin, A. Valujskikh, J. Liu, N. Muqim, Y. Xu, and M. E. Medof Decay-accelerating factor modulates induction of T cell immunity J. Exp. Med., May 16, 2005; 201(10): 1523 - 1530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Moroz, C. Eppolito, Q. Li, J. Tao, C. H. Clegg, and P. A. Shrikant IL-21 Enhances and Sustains CD8+ T Cell Responses to Achieve Durable Tumor Immunity: Comparative Evaluation of IL-2, IL-15, and IL-21 J. Immunol., July 15, 2004; 173(2): 900 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Mitchell, J. Kan-Mitchell, P. R. Morrow, D. Darrah, V. E. Jones, and M. F. Mescher Phase I Trial of Large Multivalent Immunogen Derived from Melanoma Lysates in Patients with Disseminated Melanoma Clin. Cancer Res., January 1, 2004; 10(1): 76 - 83. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
